{"product_id":"luciquiza-quizartinib","title":"LuciQuiza (Quizartinib)","description":"\u003ch2\u003eAbout Quizartinib\u003c\/h2\u003e\u003cp\u003eQuizartinib is an anti-cancer medication used for the treatment of acute myeloid leukemia. It is a small molecule receptor tyrosine kinase inhibitor. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.FLT3 mutations are among the most common mutations in acute myeloid leukemia due to internal tandem duplication of FLT3, and the presence of this mutation is a marker of adverse outcome.\u003c\/p\u003e\u003ch3\u003eAcute Myeloid Leukemia\u003c\/h3\u003e\u003cp\u003eIndicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test\u003c\/p\u003e\u003cp\u003eEach cycle is 28 days\u003c\/p\u003e\u003cp\u003eIf patient proceeds to hematopoietic stem cell transplantation (HSCT), stop quizartinib 7 days before starting conditioning regimen\u003c\/p\u003e\u003ch4\u003eInduction\u003c\/h4\u003e\u003cp\u003eMay receive up to 2 cycles of induction\u003c\/p\u003e\u003cp\u003eQuizartinib 35.4 mg PO qDay on Days 8-21, PLUS\u003c\/p\u003e\u003cp\u003e7 + 3 regimen (cytarabine 100 or 200 mg\/m\u003csup\u003e2\u003c\/sup\u003e\/day IV on Days 1-7 plus daunorubicin 60 mg\/m\u003csup\u003e2\u003c\/sup\u003e\/day IV or idarubicin 12 mg\/m\u003csup\u003e2\u003c\/sup\u003e\/day IV on Days 1-3)\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eOptional second induction\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eQuizartinib plus 7 + 3 or 5 + 2 regimen (5 days cytarabine plus 2 days daunorubicin or idarubicin)\u003c\/li\u003e\n\u003cli\u003eIf 5 + 2 regimen administered as second induction cycle, administer quizartinib on Days 6-19\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eConsolidation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eQuizartinib 35.4 mg PO qDay on Days 6-19, PLUS\u003c\/li\u003e\n\u003cli\u003eCytarabine 1.5-3 g\/m2 q12hr on Days 1, 3, and 5 for up to 4 cycles\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eMaintenance\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eQuizartinib 26.5 mg PO qDay on Days 1-14 of the first cycle if QTcF ≤450 ms\u003c\/li\u003e\n\u003cli\u003eIncrease dose to 53 mg once daily on Day 15 of first cycle if QTcF ≤450 ms\u003c\/li\u003e\n\u003cli\u003eMaintain 26.5 mg PO qDay if QTcF \u0026gt;500 ms was observed during induction or consolidation\u003c\/li\u003e\n\u003cli\u003eDuration is once daily with no break between cycles for up to 36 cycles\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954654251,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-089.jpg?v=1787022224","url":"https:\/\/xomeds.com\/products\/luciquiza-quizartinib","provider":"XOMEDS","version":"1.0","type":"link"}